Coagulation hemostasis disorders and elevated lipoprotein (a) levels in patients with arterial hypertension and multifocal atherosclerosis

Introduction. Hemostatic disorders may act as additional risk factors in patients with arterial hypertension (AH) and multifocal atherosclerotic lesion (MFAL). Elevated lipoprotein (a) (Lp(a)) levels may exacerbate procoagulant shifts.

Aim. To identify disorders in the coagulation link of hemostasis in patients with AH and MFAL, depending on the level of Lp(a).

Materials and methods. The study included 219 patients with hypertension and MFAL, median age 59 (53; 66) years, of which 110 patients with stage I–II controlled hypertension (group 1) and 109 patients with stage III controlled hypertension with a history of ischemic stroke. Depending on the level of Lp(a), patients in each group were divided into 2 subgroups with Lp(a) levels < 50 mg/dl and with Lp(a) levels above 50 mg/dl. Patients of both groups received antihypertensive, lipid-lowering, antiplatelet therapy and had comparable values of blood pressure and lipid spectrum.

Results. In group 2 patients, procoagulant shifts were significantly more often recorded, despite the constant use of antiplatelet therapy. Violations of hemostasis parameters depending on the level of Lp(a) were observed in subgroups 1b and 2b. According to the results of multiple a posteriori comparisons, the most significant hypercoagulation changes were observed in patients with stroke, as well as with Lp(a) levels > 50 mg/dl.

Conclusions. Thus, in some patients with hypertension and MFAL, despite taking antihypertensive, lipid-lowering and antiplatelet therapy, coagulation hemostasis disorders may occur. Elevated Lp(a) levels are combined with more pronounced hemostatic disorders, especially in the presence of a previous stroke. Intensification of antithrombotic therapy may be considered in such patients to prevent cardiovascular complications.

1. Miceli G, Basso MG, Rizzo G, Pintus C, Tuttolomondo A. The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. Int J Mol Sci. 2022;23(23):14914. https://doi.org/10.3390/ijms232314914.

2. Ambrosini S, Mohammed SA, Costantino S, Paneni F. Disentangling the epigenetic landscape in cardiovascular patients: a path toward personalized medicine. Minerva Cardiol Angiol. 2021;69(3):331–345. https://doi.org/10.23736/S2724-5683.20.05326-8.

3. Grover SP, Mackman N. Tissue factor in atherosclerosis and atherothrombosis. Atherosclerosis. 2020;307:80–86. https://doi.org/10.1016/j.atherosclerosis.2020.06.003.

4. Saha D, Saha S, Sergeeva EG, Ionova ZI, Gorbach AV. Tissue factor and atherothrombosis. Curr Pharm Des. 2015;21(9):1152–1157. https://doi.org/10.2174/1381612820666141013154946.

5. Ten Cate H, Guzik TJ, Eikelboom J, Spronk HMH. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovasc Res. 2021;117(9):2030–2044. https://doi.org/10.1093/cvr/cvaa263.

6. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86(8):2839–2843. https://doi.org/10.1073/pnas.86.8.2839.

7. De Luca C, Colangelo AM, Alberghina L, Papa M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Front Cell Neurosci. 2018;12:459. https://doi.org/10.3389/fncel.2018.00459.

8. Mackman N, Sawdey MS, Keeton MR, Loskutoff DJ. Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol. 1993;143(1):76–84. Available at: https://europepmc.org/article/MED/8317556.

9. Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71(2):99–112. https://doi.org/10.1016/j.ihj.2019.03.004.

10. Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res. 2014;55(4):625–634. https://doi.org/10.1194/jlr.M036566.

11. Pavlatos N, Kalra DK. The Role of Lipoprotein(a) in Peripheral Artery Disease. Biomedicines. 2024;12(6):1229. https://doi.org/10.3390/biomedicines12061229.

12. Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022;349:72–81. https://doi.org/10.1016/j.atherosclerosis.2022.04.009.

13. Amengual J, Barrett TJ. Monocytes and macrophages in atherogenesis. Curr Opin Lipidol. 2019;30(5):401–408. https://doi.org/10.1097/MOL.0000000000000634.

14. Rosenson RS, Tate A, Chen Q, Grushko O, Damodaran D, Mejia P et al. Lipoprotein(a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease.Circulation.2022;146(Suppl. 1):11904. https://doi.org/10.1161/circ.146.suppl_1.11904.

15. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786.

16. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5471.

17. Chebotareva NV, Kharionovskaya EA, Biryukova EA, Berns SA, Vuimo TA. Comparison of thrombodynamic methods and routine hemostasis tests in the evaluation of hypercoagulable syndrome in chronic glomerulonephritis. Terapevticheskii Arkhiv. 2024;96(6):565–570. (In Russ.) https://doi.org/10.26442/00403660.2024.06.202723.

18. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122(8):821–830. https://doi.org/10.1161/CIRCULATIONAHA.109.907121.

19. Celi A, Cianchetti S, Dell’Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther. 2010;8(12):1723–1729. https://doi.org/10.1586/erc.10.161.

20. Reganon E, Vila V, Martínez-Sales V, Vaya A, Lago A, Alonso P, Aznar J. Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res. 2003;112(4):217–221. https://doi.org/10.1016/j.thromres.2003.12.008.

21. Ye F, Garton HJL, Hua Y, Keep RF, Xi G. The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. Transl Stroke Res. 2021;12(3):496–511. https://doi.org/10.1007/s12975-020-00855-4.

22. Han Z, Liu Q, Li H, Zhang M, You L, Lin Y et al. The role of monocytes in thrombotic diseases: a review. Front Cardiovasc Med. 2023;10:1113827. https://doi.org/10.3389/fcvm.2023.1113827.

23. Ugovšek S, Rehberger Likozar A, Levstek T, Trebušak Podkrajšek K, Zupan J, Šebeštjen M. Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. Int J Mol Sci. 2024;25(2):736. https://doi.org/10.3390/ijms25020736.

24. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278(26):23260–23269. https://doi.org/10.1074/jbc.M302780200.

25. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745–757. https://doi.org/10.1194/jlr.R060582.

26. Risman RA, Belcher HA, Ramanujam RK, Weisel JW, Hudson NE, Tutwiler V. Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen. Biomolecules. 2024;14(2):230. https://doi.org/10.3390/biom14020230.

27. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692–711. https://doi.org/10.1016/j.jacc.2016.11.042.

28. Muramatsu Y, Minami Y, Kato A, Katsura A, Sato T, Kakizaki R et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study. Int J Cardiol Heart Vasc. 2019;24:100382. https://doi.org/10.1016/j.ijcha.2019.100382.

29. Ferretti G, Bacchetti T, Johnston TP, Banach M, Pirro M, Sahebkar A. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J Cell Physiol. 2018;233(4):2966–2981. https://doi.org/10.1002/jcp.26050.

30. Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503. https://doi.org/10.1016/j.atherosclerosis.2015.08.021.

31. Shiyovich A, Berman AN, Besser SA, Biery DW, Kaur G, Divakaran S et al. Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. J Am Heart Assoc. 2024;13(10):e034493. https://doi.org/10.1161/JAHA.123.034493.